Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of obscure etiology. Multiple genetic studies have been conducted to advance our understanding of the disease, employing a variety of techniques such as linkage mapping in families, to genome-wide association studies and sequencing based approaches such as whole exome sequencing and whole genome sequencing and a few epigenetic analyses. While major progress has been made, the majority of the genetic variation involved in ALS is yet to be undefined. The optimal study designs to investigate ALS depend on the genetic model for the disease, and it is likely that different approaches will be required to map genes involved in familial and sporadic disease. The potential approaches and their strengths and weaknesses are discussed.
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by selective loss of upper and lower motor neurons (common clinical manifestations of ALS are shown in Fig. 1 ). The disease typically has a late onset and is often fatal within 3 to 5 years. No effective treatments exist for ALS; the only current treatment is riluzole, which is thought to affect glutamate metabolism and only modestly extends survival time (Miller and others 2012) . The worldwide incidence of ALS is approximately 0.3 to 7.0 new cases per 100,000 each year (Cronin and others 2007) . Nearly 10% of ALS cases are classified as familial ALS (fALS) (Byrne and others 2011), wherein a family history of the disease is known. In these families, the pattern is primarily consistent with autosomal dominant inheritance, although other hereditary patterns have been found (Siddique and Ajroud-Driss 2011) . Approximately half of familial cases can be explained by specific genes, the majority of which appear to be rare highly penetrant de novo mutations in each family involved. The 90% of ALS cases where no family history is present are termed sporadic ALS (sALS). The genetic etiology of both sALS and nearly ~30% of fALS (European descent) remains obscure. Whether sALS is primarily polygenic, because of highly penetrant de novo mutations or inherited mutations with low penetrance is unclear, and this knowledge will be critical in the design of future genemapping studies. Detailed information regarding ALSrelated genes is available via the amyotrophic lateral sclerosis online genetics database (http://alsod.iop.kcl. ac.uk/), the ALS mutation database (https://reseq.lifesciencedb.jp/resequence/SearchDisease.do?targetId=1), and the ALSGene database (http://www.alsgene.org).
Exploring the genetic etiology of ALS has provided fundamental insights into the process underlying neuron degeneration and majority of our current knowledge of ALS. On this basis, considerable efforts have been devoted to unravel pathophysiological mechanisms. Multiple pathogenic processes have been reported that support the view of multiple routes to a common endpoint of progressive upper motor neuron and lower motor neuron loss (Fig. 2) .
Since the discovery of mutations in the SOD1 gene causing fALS in 1993 (Rosen and others 1993) , a growing number of causative genes and related loci have been identified (Table 1) , including TARDBP, FUS and C9orf72. A breakthrough in the understanding of ALS pathogenesis was the discovery that TDP-43 is a central component of the ubiquitin-positive neuronal inclusions that are the pathological hallmark in ALS (Neumann and others 2006) . TDP-43 is an RNA-binding protein that is encoded by the gene TARDBP and mutations were subsequently found in rare ALS case. The discovery of ALS causing mutations in several other genes whose encoded proteins are involved in RNA processing has further implicated this molecular pathway in the pathogenesis in ALS. These include mutations in FUS, encoding an RNA-binding protein with similarity to TDP-43 (Kwiatkowski and others 2009; Vance and others 2009 ) and a repeat expansion in C9orf72, associated with RNA foci in cells from ALS cases (DeJesus-Hernandez and others 2011). A growing number of genes have been implicated in ALS by discovery of rare sequence variants in ALS cases, including VCP (Wu and others 2012) and PFN1 , although molecular evidence supporting a role as an ALS causative gene is not entirely convincing for all genes and requires further validation.
In order to advance our understanding of the aetiopathogenesis of ALS, extensive candidate gene and hypothesisfree gene-mapping studies have been pursued. In recent years, revolutions in genetic techniques have taken place. The development of genome-wide association studies (GWAS) has provided a powerful tool for the identification of common variants associated with disease, and next-generation sequencing (NGS) methods have proven similarly effective in mapping mutations underlying single gene diseases. Multiple GWAS and NGS studies have collectively identified a number of novel genetic variants associated with increased risk of ALS development. These approaches, that make assumptions about the underlying genetic architecture Many of the initial pathological changes in models of ALS occur in the peripheral motor system, supporting a "dying-back" view of pathogenesis, though a causal primacy of lower motor neuron over upper motor neuron degeneration remains an issue of debate. The transgenic SOD1 mouse model has been used extensively to dissect the likely pathogenic mechanisms. Many of these illustrated pathways are mechanisms of cell death common to a range of neurological disorders whereas more recent genetic discoveries have yet to be elucidated at a molecular level. Pathophysiological mechanisms involved in ALS might include combinations of glutamate excitoxicity, generation of free radicals, mutant enzymes, as well as disruption of axonal transport processes and mitochondrial dysfunction. Mutations in several ALS causative genes are related to the formation of intracellular aggregates. Mitochondrial dysfunction, which is associated with increased production of reactive oxygen species and aggregates of SOD1, might induce increased susceptibility to glutamate-mediated excitotoxicity, disturbance in energy production and apoptosis. Activation of microglia results in secretion of cytokines resulting in further toxicity. of disease especially for sporadic cases, can be complex to perform (Hardiman and others 2007) , and depend on accurate clinical phenotyping for success. Thus, whilst many robust associations have been made with rare mutations and common variants in ALS, false positive findings have also occurred (Garber 2008) . Given this context it is important to examine the performance and limitations of GWAS along with the expectations for NGS in the study of ALS.
Are Sporadic and Familial ALS Different?
The genetic architecture of common diseases can be investigated by studying the recurrence rate in relatives of affected individuals (Risch 1987) . A twin study has shown that for ALS the concordance rate in identical monozygotic twins is ~10%, whereas the concordance ). The mutations/s segregates with disease, is not found in normal samples, and mutations were subsequently found in sALS or other small families; 2. Variants were found to segregate in multiple small families (but were too small to achieve genome-wide significance in linkage analysis) as well as found in multiple sporadic cases and are not found in normal samples; 3. Gene contains variants that segregate in multiple small families but have not been reported in sporadic cases, and are not found in normal samples; 4. Variants described in one small family and multiple sporadic cases and are not found in normal samples. Functional tests assessing the affect of the mutation on the protein function support a role in ALS; 5. Mutations have been reported in multiple sporadic cases and not in normal samples. Functional tests assessing the affect of the mutation on the protein function support a role in ALS; 6. Rare variants have been found in the gene in only one family; 7. copy number variants (CNV)/particular alleles present in ALS patients significantly more than control. rate in dizygotic twins is very low (0/122 twins) as is the parent-offspring concordance rate (~1%) (Al-Chalabi and others 2010). From the twin concordance values, the heritability of ALS has been calculated to be 61%, taking into account the low population prevalence of the disease (Al-Chalabi and others 2010). For monogenic autosomal diseases, the parent-offspring rate is generally high unless the penetrance is low (Risch 1990a (Risch , 1990b ). Thus the low parent-offspring and twin concordance rates are most consistent with models involving either multiple variants, either common or rare, especially variants with low penetrance, contributing to each case, rather than single highly penetrant variants in each individual. The boundary between sporadic and familial ALS is becoming far more blurred than their nomenclature suggests. Although it has been reported that 10% of ALS is familial, when the genealogy of sALS cases is investigated more thoroughly, the prevalence of a family history increases to 20% in some prospective studies (Chio and others 2011; van Es and others 2010). Establishing familiality is difficult in late onset diseases, and it is likely that this leads to underestimation of the familiality of ALS. It is often quite difficult for adult children of ALS patients to accurately recall their parent's symptoms, particularly if decades have passed since the event, which occurred when the diagnosis of ALS may not have been considered.
The idea that sALS and fALS may share a diverse genetic aetiology is consistent with the observation that sALS and fALS are clinically indistinguishable (Andersen and others 1997) , and because of increasing demonstration that "sporadic" cases are often caused by the same mutations that have previously been reported in familial cases. Familial and sporadic cases share histopathological characteristics; for example, superoxide dismutase 1 (SOD1)-positive and TAR DNA-binding protein 43 (TDP-43)-positive inclusions have been found in both sALS and fALS (Bosco and others 2010; Forsberg and others 2010). Moreover, first-degree relatives of patients with ALS have an increased incidence compared with unrelated individuals (Fallis and others 2009). Additionally, the hexanucleotide repeat expansion mutation in the C9orf72 gene is associated with a founder haplotype. The expansion is found both in familial cases and in a high proportion of "sporadic" ALS cases (21% of Finnish sALS) (Renton and others 2011), and, albeit at low frequency, in control populations (prevalence of expansions 0.15% in 1958 British Birth Cohort) (Beck and others 2013) . The C9orf72 expansion occurs on a common risk haplotype, which is prone to expansion of the hexanucleotide repeat for reasons that are not understood. Thus whilst the common founder haplotype is prevalent in the community, further mutation (expansion of the hexanucleotide repeat) on this haplotype may lead to ALS, and would at least partially explain the occurrence of sALS due to C9orf72 expansions in families with no previous history of the disease (DeJesus-Hernandez and others 2011). The alternative is that the repeat expansion is not fully penetrant and modifier loci or environmental factors are also required for C9orf72 repeat expansions associated ALS pathogenesis.
Combined, this evidence indicates that sALS diagnosis does not exclude the possibility of familial inheritance even with "definite" negative familial histories. The term "sporadic" has also been used for other neurological disorders such as autism, in which a high degree of genetic heterogeneity has now been uncovered (O'Roak and others 2012). We agree with the suggestion that the term "sporadic" is inappropriate as it suggests only non-genetic causes, whereas the term "isolated" ALS might be more accurate as it encompasses environmental and/or genetic causes.
Prevalent Heterogeneity in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis demonstrates both clinical and genetic heterogeneity, but to date genetic explanations for the clinical heterogeneity have been incomplete.
Three clinical variants are widely recognized, including progressive bulbar palsy (PBP), classic onset and progressive muscular atrophy (PMA) (del Aguila and others 2003). By and large, bulbar onset appears to advance more rapidly and PMA may have a better prognosis (del Aguila and others 2003; Norris and others 1993). Besides these three, other forms have been recognized in recent years. Brachial amyotrophic diplegia (flail arm syndrome, FA) and the pseudopolyneuritic variant (flail leg syndrome, FL) are instructive examples. Compared with classic type, FA and FL have a prolonged course (Wijesekera and others 2009 ). Furthermore, these clinical variants appear to have a male predominance, which may suggest that other gender-related genes are involved, although such genes are yet to be identified (Gamez and others 1999) .
Recent genetic studies have taken clinical heterogeneity into account, but have yet to identify individual variants or genomic profiles associated with different ALS clinical patterns (Dunckley and others 2007; Kwee and others 2012 ). An Italian study (Orsetti and others 2011) involving 228 ALS patients reported a potential correlation between the upper motor neuron-predominant phenotype and KIFAP3. However, these findings have not been replicated in subsequent studies (Table 3 ). This may be because in some studies the clinical subgroups were not clearly defined in the same manner as the Italian study, and in others the study power was likely insufficient.
Whatever the explanation, clear genotype-phenotype correlation to explain the different presentations is lacking.
Studies of ALS have been particularly successful in identifying disease-causative mutations (Table 1) . Clinical heterogeneity is seen in unrelated ALS cases that share the same mutation, but also in carriers from within the same family. On the other hand families with mutations in different genes are often clinically indistinguishable. In addition to the locus heterogeneity, there is also extensive allelic heterogeneity. For example, at least 160 disease-causative mutations in SOD1 have been reported (Birve and others 2010; Zinman and others 2009). If genetic or locus heterogeneity is as extensive in sporadic ALS, genetic studies will struggle to identify the genes involved, unless quite large case and control cohorts are studied.
Amyotrophic Lateral Sclerosis Studies in Different Ethnic Populations
Genetic differences between ethnic groups are often a nuisance in genetic studies. Nonetheless, they can be useful tools where the variation in linkage disequilibrium and polymorphism frequencies between populations provides useful contrasts that can be informative in identifying key disease-associated variants. There are no apparent differences in the incidence or prevalence of ALS between ethnic groups. However, several spatial clusters of ALS have been reported that may be explained by a higher frequency of particular mutations in geographical regions. A spatial cluster of ALS in south-eastern Finland (Sabel and others 2003) is likely explained by the high occurrence of the C9orf72 hexanucleotide repeat in ALS cases from Finland. Similarly, although the C9orf72 repeat expansion is generally rare in Japanese ALS cases, it has been reported in cases from the Kii peninsula where another cluster had also been observed (Yoshida and others 1998). Perhaps of more interest for disease progression is the SOD1 mutation (D90A) that has been shown to be responsible for slowly progressive, autosomal recessive ALS in Sweden and Finland (Andersen and others 1997) . A total of 1% to 2.5% of the population are heterozygous carriers of this mutation, yet do not develop ALS. However, in other geographical locations, heterozygous carriers of the same mutation develop classical ALS (Robberecht and others 1996) . Whether this is caused by environmental effects or modifier genetic effects is unknown. Thus, there is likely to be genetic heterogeneity between ethnic groups, providing new information about the genetic causes of a disease. To date nearly all large-scale genetic studies in ALS have been performed in populations of European descent, with only limited studies performed in Asians, and none that the authors are aware of in African Americans. Such studies would be beneficial in elucidating the genetic contribution to ALS globally.
Genome-wide Association Studies in Amyotrophic Lateral Studies
Traditional genetic strategies such as linkage studies or candidate gene sequencing have had major success in finding mutations in familial ALS. However, their potential is limited by the low availability of families with recurrent disease, challenges associated with family studies in late onset diseases, and by the low power of linkage analysis to identify low-penetrant variants. As cases are often misdiagnosed and/or have died before recurrence occurs within individual families, few families with DNA samples from multiple affected and unaffected members from multiple generations are available. The variability in the age of onset, even within families, means that coding unaffected members of families can be misleading, when they may develop ALS later in life. Additionally there are now several examples of ALS mutations with incomplete penetrance (for example in SOD1 (Gamez and others 2011) and TARDBP (Orru and others 2012)), the presence of which can also affect linkage studies. Given these challenges with traditional linkage mapping approaches, and the possibility that many sALS cases may be because of low penetrance, possibly common founder variants, in recent years alternate methods involving GWAS and exome sequencing have been employed to identify the genetic variants.
The Design of Amyotrophic Lateral Sclerosis GWAS
Genome-wide association studies identify loci associated with disease where cases or controls share stretches of DNA (haplotypes) in which a disease-causing mutation has occurred in a distant common founder. By typing SNPs across the genome, these disease-associated haplotypes are identified by differences in frequencies of SNPs between cases and controls because of the marker SNPs being found on the same haplotype as the disease-causing variant, a feature termed 'linkage disequilibrium'. Association in GWAS studies may thus represent true association (where the genotyped, associated SNP is directly involved in the disease), linkage disequilibrium (where the genotyped, associated SNP is merely a marker for a haplotype bearing the true disease-causing variant), population stratification (where differences in ethnicity between cases and controls lead to spurious associations), technical artifacts in the genotyping (such as batch effects, differential missingness), or cryptic relatedness (where the assumption that cases and controls are not closely related to one another is not met, leading to inflation of association test statistics). Careful quality control checks of GWAS data have been developed, and if these are used then findings that achieve genome-wide significance (generally thought to be P < 5 × 10 −8 , although this does depend on the prior probability of a true positive finding) have generally proven robust and reproducible.
Sample size requirements for GWAS are large and challenging to achieve, particularly for low frequency diseases such as ALS (Purcell and others 2003) (Figure 3) . For most diseases, this has led to the formation of large consortia pooling resources to achieve adequate power. Where separate studies are performed, meta-analysis methods and software for either the original genotype data or summary statistics have been developed to achieve sufficient power. There has been some success employing GWAS in ALS (Table 2) , and some of that raw data has been made publicly available to augment resource for other studies of ALS. The largest GWAS to date in ALS involved 6100 cases and 7125 controls (Fogh and others 2014) . Although this is evidently a large study, the sample size requirement presented in Figure 1 suggest that even larger studies will be required to identify further loci, particularly to identify low frequency variants, even if they have quite high penetrance. For example, to achieve 80% power to identify a variant with minor allele frequency of 1% and odds ratio for disease of 5 will require >10,000 cases to be studied! Such sample sizes have been achieved for diseases less common than ALS. For example, in Crohn's disease, which has a prevalence of 0.1%, more than 77,000 cases have been reported in a single study (Jostins and others 2012).
As discussed above there are unique challenges in recruiting patients with ALS that make it particularly difficult to achieve such large numbers, but given the great potential of genetics in this disease, greater emphasis on recruitment is required, and further collaborative studies encouraged. In addition, large GWAS meta-analytical studies including both Caucasian and non-Caucasian populations are likely to be informative.
The Results from GWAS
In the past 6 years, a conservative estimate of more than 8000 ALS patients (including patients of white European and Asian descent), and many more control subjects, have been involved in large scale ALS studies. This has resulted in the identification of SNPs that appear to be associated with the disorder. The discovery of association with the C9orf72 region is the most well known of these. In 2010, three ALS-GWASs reported a novel susceptibility locus associated with the disease on chromosome 9p where 100 1,000 10,000 100,000 1,000,000 10,000,000 non-specific neurodegenerative disease syndromes in addition to FTD and ALS (Beck and others 2013). The above experimental conclusions become even more convincing when the data are subjected to metaanalysis and pooled analysis. The need for such approaches is highlighted by the high rate of non-replication of findings between ALS GWAS studies (Table 3) , which very likely represent type 1 errors due to insufficient sample size and statistical power. This is a particular problem in genetic studies of ALS, likely because the disease is rare and it is hard for individual groups to achieve adequate sample sizes. Indeed with the exception of the chromosome 9p21 locus, most associated SNPs or genes show poor replication in different populations. This is also an issue in transethnic studies, where for example even the findings for the chromosome 9p21.2 locus are inconclusive in Asian populations probably because the repeat expansion is rare. Robustly proven differences in associations at specific loci can be highly informative regarding the primary disease-causative variants, which can be hard to pinpoint in specific populations, particularly at loci with extensive linkage disequilibrium surrounding them.
Copy Number and Structural Variants in Amyotrophic Lateral Sclerosis
Microarray SNPs used in GWAS have modest capability to genotype copy number variants (CNVs) and other structural variants. When inherited, these are typically in linkage disequilibrium with SNPs and at most common loci have been detected by GWAS even if the CNV has not been typed itself (Wellcome Trust Case Control Consortium and others 2010). For ALS only a handful of CNV analyses have been reported. The most well studied CNV is of the SMN1 gene in which loss of function mutations cause autosomal recessive spinal muscular atrophy. Several reports suggested that duplication of the SMN1 gene is found at a higher frequency in ALS patients (Corcia and others 2002; Corcia and others 2006; Veldink and others 2005) and an association of ALS with SMN1 copy number was later confirmed in an analysis of 3500 ALS cases (Blauw and others 2012) . Aside from the SMN1, other CNV analyses in ALS have not had sufficient power to confirm correlations of rare events (Cronin and others 2008) . The lack of CNV associations with ALS are likely because of limits of current methods for genotyping CNVs, or that they are rare rather than that they do not occur. Recently, whole genome sequencing successfully uncovered de novo CNVs in subjects with intellectual disability (Gilissen and others 2014) , and a similar approach may be required to uncover ALS CNVs, if they exist.
Genome-wide Association Studies and Rare or De Novo Variants
Given the limited sample sizes studied and typically weaker linkage disequilibrium around rare and low frequency variants, association signals from such variants are frequently missed by GWAS. Of particular relevance to ALS, GWAS is not capable of detecting de novo sporadic mutations that may be responsible for a significant fraction of cases, as opposed to variants arising in a distant common founder.
Thus while GWAS is a powerful hypothesis-free approach to identifying genetic variants in common human diseases, it is not capable of identifying all variants, including a range of variants already known to be involved in ALS.
Sequencing for Amyotrophic Lateral Sclerosis Gene Mapping
As GWAS studies are poor at identifying low frequency (minor allele frequency [MAF] <5%) and rare (MAF <1%) alleles, it has been suggested that large numbers of such variants may explain the failure of GWAS to identify the variants responsible for a large proportion of the heritability of individual diseases (Manolio and others 2009 ). This remains however an unproven hypothesis, with little evidence to date to support the existence of multiple low frequency or rare variants with greater penetrance than common variants. The few reported examples of highly penetrant rare alleles have generally occurred in genes already known to be associated with disease through common variant studies, such as IL23R (Momozawa and others 2011), CARD9 (Rivas and others 2011), and IFIH1 (Nejentsev and others 2009 ). This may represent experimental bias as sufficiently large studies to detect rare variants are still works in progress. In ALS though, it is clear that rare highly and lowly penetrant variants do contribute significantly to the disease-these are the variants that cause fALS, and are increasingly being identified in sALS.
Next-generation sequencing techniques, including whole exome sequencing (WES) and whole genome sequencing (WGS) represent a powerful new paradigm with regard to addressing monogenic disorders. These techniques have enabled gene-mapping studies for rare genetic diseases to be performed in the absence of multigeneration family material. Instead, either small numbers of unrelated affected individuals or small families can now be successfully investigated. This has proven revolutionary in monogenic disease research, stimulating another boom in gene discoveries for diseases that had previously not been mappable because of insufficient family material. The approach has already proven productive in fALS, where it has been used to identify disease-causing mutations in VCP and PFN1 (Johnson and others 2010; Wu and others 2012) that are strongly supported as ALS-causing mutations from functional studies. Additionally, a WES study using samples from 47 sporadic ALS cases and their unaffected parents, have identified de novo mutations in several candidate genes, including as SS18L1, encoding proteins that regulate chromatin (Chesi and others 2013) .
The same approaches using NGS to map monogenic diseases are now being used to map rare high penetrant variants in more genetically complex diseases, such as sALS. Unlike monogenic diseases, ALS creates a new challenge because of the genetic and locus heterogeneity and the possibility that ALS is oligo-or polygenic, with more than one disease-causing variant operating in individuals. This requires much larger sample sizes to be studied and more complex analyses to be performed, inevitably involving greater cost. However, given that ALS may be substantially caused by rare or even de novo mutations, these challenges will have to be faced to advance our understanding of the genetics of this disease. In the past arguments for variants being disease-causing have been strengthened by evidence of segregation with disease in fALS, along with identification of mutations in sporadic cases. For PRPH and EWSR1, mutations have only been described in sALS; however, convincing functional data accompanied the variant discovery. Functional methods for determining the relevance of rare sequence variants identified by NGS to ALS pathogenesis will continue to be necessary in the study of genetic causes of sALS. The diagnostic benefits that NGS will provide for ALS patients and their neurologists are obvious. Currently the average time from symptom onset to confirmed diagnosis for ALS patients is nearly 1 year, a time in which misdiagnosis and sometimes even invasive surgery may occur (Paganoni and others 2014) . Early diagnosis will be vital for clinical trials where early treatment before significant damage has occurred will be of utmost importance. Early diagnosis may be facilitated by sequencing early symptomatic cases, or by screening in families known to carry high penetrant variants. Furthermore, knowledge of the genetic cause of ALS in patients participating in clinical trial will informative, where in the context of a genetically heterogeneous disease success or failure of treatments may depend on the original genetic cause. Until treatments reach the clinic, the multitude of researchers using donated material from ALS patients to try to understand why motor neurons degenerate, will benefit by being able to group samples based on genetics to more meaningfully interpret data generated.
Limitations of Next-Generation Sequencing in Amyotrophic Lateral Sclerosis
Although there are clear advantages to NGS, it is not without drawbacks. As the name implies, WES is designed to capture the whole exome. In reality it does not, and about 5% of the exome is not captured in typical exome sequencing experiments. Furthermore, not all monogenic diseases are caused by mutations in coding regions, and therefore may not be detected using exome sequencing. An additional technical challenge is that WES using short-read sequencing technologies such as Illumina sequencing chemistry has difficulties in sequencing repeats and insertion/deletions, as the short reads cannot be unambiguously aligned against reference genomes. Some relevant examples of the limitations of WES exist in ALS gene-mapping include the following: 
Genome-wide Methylation Analysis
Several different methods involving either microarrays or DNA sequencing now enable genome-wide characterization of DNA methylation. Epigenetic variation including DNA methylation is a major determinant of gene transcription. Improved methods to assess DNA methylation in particular has led to increasing interest in the role of epigenetic variation in human disease, including ALS (Figueroa-Romero and others 2012). An early microarray based analysis of methylated DNA immunoprecipitated from post-mortem brain found differential gene methylation in ALS cases (Morahan and others 2009) and a second using ALS spinal cord reported changes in global methylation and hydroxymethylation (Figueroa-Romero and others 2012). These studies represent an initial identification of epigenetic regulatory changes in ALS, however, were only performed on 10 and 12 ALS samples, respectively. Larger studies with more sensitive and robust methods are clearly required to uncover the contribution of epigenetics to ALS.
Aside from genome-wide methylation analyses, several gene specific analyses of CpG methylation within promoters of ALS genes and candidate genes have been performed. No difference in DNA methylation was observed in ALS cases in the promoter regions of SOD1, VEGF (Oates and Pamphlett 2007) and EAAT2 (Yang and others 2010) . However, CpGs upstream of the C9orf72 repeat expansion in some expansion carriers were hypermethylated and the corresponding mRNA was down-regulated in a limited number of samples tested (Xi and others 2013) . Methylation of upstream CpG islands is not novel in terms of repeat expansion mutations and the role that methylation at the C9orf72 locus plays in ALS pathogenesis is yet to be determined and requires further analysis in larger cohorts of carriers.
Other Methods Combined with Whole Genome Strategies
Commonly, alleles showing a correlation between allele load and expression levels are defined as expression quantitative trait loci (eQTL). conducted a two-stage genome-wide screen for eQTLs associated with ALS. Data from a two-stage GWAS were combined to prioritize eQTLs identified in the first stage. While identifying candidate genes for sporadic ALS, most notably CYP27A1, the study demonstrated the potential of an integrated approach in identifying causative genetic variants in ALS.
Both methylation and expression analyses in ALS suffer from issues related to tissue sampling because the site of disease pathology is not amenable during the life of the patients. Postmortem material, although valuable, represents end-stage of disease when significant damage and neuron loss has already occurred. It is also difficult to obtain the large numbers of post-mortem samples required for genome-wide analyses. Other sources of RNA and DNA that are more suitable for the large studies required for such a genetically and clinically heterogenous disorder as ALS will need to be considered.
Expectation for Future Amyotrophic Lateral Sclerosis Genetic Studies
Genetic discoveries in ALS have provided major advances in our understanding of the diseases causation, and the development of new methods for gene mapping particularly using high-throughput sequencing promises much. There is also a clear need to perform further studies in populations of different ethnicity. Systems biology approaches including multiple modalities such as DNA sequencing, transcriptomics, proteomics and epigenomics are likely to be useful, particularly with functional analysis of the mechanisms by which genetic mutations cause ALS. As ever there is no "one-size-fits-all" solution to ALS research, but the increasing capability of our research tools is bringing major advances to studies of this disease. In other disease areas such as immune-mediated diseases, success in gene-mapping has been so great in the past 5 years of the GWAS era that the bottleneck has clearly moved on to determining how disease-associated variants lead to disease. The authors expect that this will similarly be the problem facing ALS research in the near future.
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